Creative Planning Acquires 887 Shares of Novartis AG (NVS)

Creative Planning raised its holdings in Novartis AG (NYSE:NVS) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 59,777 shares of the company’s stock after purchasing an additional 887 shares during the period. Creative Planning’s holdings in Novartis were worth $5,019,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. Parnassus Investments CA lifted its holdings in shares of Novartis by 18.5% in the third quarter. Parnassus Investments CA now owns 9,447,817 shares of the company’s stock valued at $811,095,000 after purchasing an additional 1,477,168 shares in the last quarter. Fisher Asset Management LLC raised its position in shares of Novartis by 2.0% in the third quarter. Fisher Asset Management LLC now owns 6,632,984 shares of the company’s stock valued at $569,442,000 after buying an additional 127,049 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Novartis by 3.1% in the second quarter. The Manufacturers Life Insurance Company now owns 5,036,427 shares of the company’s stock valued at $420,390,000 after buying an additional 151,115 shares during the last quarter. BlackRock Inc. raised its position in shares of Novartis by 25.3% in the second quarter. BlackRock Inc. now owns 3,549,783 shares of the company’s stock valued at $296,299,000 after buying an additional 717,186 shares during the last quarter. Finally, State Street Corp raised its position in shares of Novartis by 2.3% in the second quarter. State Street Corp now owns 3,046,276 shares of the company’s stock valued at $254,273,000 after buying an additional 68,834 shares during the last quarter. 10.85% of the stock is currently owned by institutional investors.

Novartis AG (NYSE:NVS) opened at $86.94 on Friday. Novartis AG has a 52-week low of $69.53 and a 52-week high of $87.29. The company has a debt-to-equity ratio of 0.32, a quick ratio of 0.81 and a current ratio of 1.08. The company has a market cap of $226,090.00, a P/E ratio of 30.94, a P/E/G ratio of 2.32 and a beta of 0.74.

Novartis (NYSE:NVS) last issued its quarterly earnings results on Tuesday, October 24th. The company reported $1.29 EPS for the quarter, topping the consensus estimate of $1.25 by $0.04. Novartis had a net margin of 13.73% and a return on equity of 15.77%. The firm had revenue of $12.41 billion during the quarter, compared to analyst estimates of $12.21 billion. During the same quarter in the prior year, the business posted $1.23 earnings per share. Novartis’s revenue for the quarter was up 2.4% compared to the same quarter last year. equities research analysts expect that Novartis AG will post 4.79 EPS for the current fiscal year.

A number of research firms have recently weighed in on NVS. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novartis in a research report on Thursday. Nord/LB reissued a “neutral” rating on shares of Novartis in a research report on Tuesday, January 2nd. UBS Group reissued a “neutral” rating on shares of Novartis in a research report on Monday, January 15th. Barclays lowered shares of Novartis from an “equal weight” rating to an “underweight” rating in a research report on Wednesday, October 25th. Finally, Leerink Swann boosted their price objective on shares of Novartis from $89.00 to $91.00 and gave the company a “market perform” rating in a research report on Monday, October 23rd. Five equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and four have given a buy rating to the company’s stock. Novartis presently has a consensus rating of “Hold” and an average price target of $85.32.

COPYRIGHT VIOLATION WARNING: “Creative Planning Acquires 887 Shares of Novartis AG (NVS)” was first published by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The correct version of this article can be accessed at https://sportsperspectives.com/2018/01/20/creative-planning-acquires-887-shares-of-novartis-ag-nvs.html.

About Novartis

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.

Want to see what other hedge funds are holding NVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novartis AG (NYSE:NVS).

Institutional Ownership by Quarter for Novartis (NYSE:NVS)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply